ELife: uncover the key role of camp in regulating immune response

February 7, 2020 / BIOON / -- recently, an international magazine published in eLife In the previous research report, scientists from the University of California revealed the key role of cyclic AMP (cAMP) in regulating the immune response of the body The research results show that camp can change the response of T-helper cells (Th cells) in the immune system to threats by inhibiting gene transcription of key proteins Relevant research results may help to develop New ways to treat diseases by controlling the immune system Photo source: cc0 public domain Th cells can help the immune system recognize that infected cells are destroyed by killer T cells Previous studies have shown that low levels of camp can promote the immune system to produce more Th2 cells, while high levels of camp can promote the production of Th17 cells In the current study, researchers analyzed the molecular mechanism behind the regulation of these Th cell responses by camp, Researchers Lee said that using camp to process cells or reprogram Th2 cells and Th17 cells can also do this by inhibiting IRF4 and KLF4 IRF4 and KLF4 are two key transcription factors, which can turn on the expression of genes that need to produce Th2 cells Later, researchers found that through genetics The engineered mice without IRF4 carry more Th17 cells, while the mice treated with IRF4 can recover Th2 cells Researcher Eyal Raz said that in this study, we have revealed the new role of camp in the flexibility of the immune system, and the relevant research results are expected to help develop new therapeutic means to control the immune response of the body; for example, drugs that enhance cAMP level can help people from bacteria by enhancing the level of Th17 cells During the recovery process of sexual infection, drugs that reduce cAMP level may help to effectively treat parasite infection, which requires a large number of strong Th2 cell responses Finally, the researchers said that the results of this study show that drugs that inhibit IRF4 and KLF4 can be used to treat a variety of blood cancers, which are often derived from B cells in the bone marrow; in the later study, the researchers will continue to conduct in-depth research to develop more new types of cancer treatment Original sources: jihyung Lee, Junyan Zhang, young Jun Chung, et al Occupation of IRF4 in nominal cells by PRR in dependent and - dependent signals inhibit Th2 and promote Th17 responses, eLife (2020) Doi: 10.7554/elife.49416